The role of Anastrol (Anastrozole) is generally to assist with managing hormone receptor-positive malignancies in postmenopausal women. Its use is relevant in contexts marked by increased discomfort or tension related to disease activity. The medication is used to help with managing the growth of breast cancer cells that are influenced by hormones. The primary benefit is its role in systematic management, which contributes to easing the overall symptom load.

The therapeutic use of Anastrol is commonly applied in addressing hormone receptor-positive breast cancer in its early-stage (adjuvant setting) and is relevant as a primary or sequential treatment for advanced or metastatic disease. It is also considered relevant in situations where patients experience the risk of developing breast cancer in certain high-risk postmenopausal women.

Key Therapeutic Domains

This medication is commonly used to manage the risk of the cancer returning (recurrence) after the initial diagnosis and treatment. It is applied to address disease progression and to assist with managing challenging manifestations in advanced cases. The primary therapeutic role is to support management of the disease in contexts involving systemic imbalance.

“The primary goal is supporting long-term stability and easing the overall symptom load associated with the disease.”

Quick Fact: Support for Disease Management This treatment assists with maintaining functional stability and supports general well-being in situations where patients experience symptoms.

The primary benefit is its role in systematic management, which contributes to easing the overall symptom load. This supports the patient during difficult episodes by easing distress.

Regulatory References

1. MedlinePlus Drug Information overview

Official Eligibility Profile

Regulatory agencies define strict population rules for the use of Anastrol (Anastrozole), focusing exclusively on eligibility criteria and contraindications established by governmental labeling.

Populations Allowed and Restricted

Anastrol is officially designated for the Adult population, specifically postmenopausal women whose endocrine status has been verified. Use in children and adolescents is officially not recommended by regulatory bodies, as safety and efficacy have not been established in these age groups.

Contraindicated Status	Excluded Population
Absolute Prohibitions	Premenopausal women, Pregnant women, and Lactating/Breastfeeding women.
Excipient/Comorbidity	Patients with hypersensitivity to anastrozole or rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Conditional Use and Organ Function Restrictions

Certain populations require caution due to limited data or increased exposure risk. Regulatory documents advise caution for patients with moderate or severe hepatic impairment and those with severe renal impairment (typically defined by Creatinine Clearance below 30 mL/min or 20 mL/min). Furthermore, use for primary prevention is restricted in women diagnosed with severe osteoporosis or multiple vertebral fractures.

The official regulatory profile for Anastrol (Anastrozole) documents specific constraints regarding co-administration with other medicines and products. Co-administration with estrogen-containing therapies and the medicine Tamoxifen is formally contraindicated. These combinations are prohibited because they may diminish the desired anti-estrogenic action of Anastrol through pharmacodynamic antagonism. Furthermore, the co-administration of Tamoxifen has been shown to reduce the plasma concentration of Anastrozole by 27%. Due to this evidence, the simultaneous use of these agents is not permitted.

Regarding metabolic interactions, regulatory data indicates that Anastrol is unlikely to cause clinically significant inhibition of major Cytochrome P450 enzymes, such as CYP1A2, 2C8/9, and 3A4, when administered at its therapeutic dose. This suggests the medicine is not generally a relevant perpetrator of drug-drug interactions through this pathway.

The official labeling notes that the drug can be taken with or without food, as food only affects the rate but not the extent of absorption. However, patients should avoid co-administering oestrogen-containing herbal products or supplements, as these may diminish the intended pharmacological effect. A population-specific constraint exists for patients with stable hepatic cirrhosis, who exhibit an apparent oral clearance approximately 30% lower than in individuals with normal liver function, leading to altered exposure.

How Anastrol works: The Biological Mechanism

Selective Inhibition of Aromatase

This section details Anastrol's main biological target: the aromatase enzyme (CYP19A1). The drug functions as a nonsteroidal, competitive inhibitor, binding reversibly to the enzyme's active site to prevent the conversion of androgens into estrogens, thereby inhibiting the synthesis of circulating estrogen hormones.

Disrupting the Steroidogenesis Pathway

This mechanism modulates the core steroidogenesis cascade, focusing on the resulting reduction of estradiol (E2) levels throughout the body, particularly from peripheral sources like adipose tissue and muscle. This interruption results in a state of significantly reduced estrogen levels.

Downstream Endocrine Feedback

The reduction of circulating estrogen due to peripheral synthesis inhibition engages the Hypothalamic-Pituitary-Gonadal (HPG) axis through the loss of negative feedback. This results in a compensatory release of pituitary hormones (Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH)), which subsequently influences the resulting endocrine balance.

Anastrol (Anastrozole) is administered as an oral agent and is designed for standardized, long-term use. The approved regimen for adults is a fixed dose of one 1 mg tablet taken once daily. This consistent frequency is required to maintain systemic levels, and the tablet is taken at approximately the same time each day.

The tablet must be swallowed whole with water and should not be crushed or chewed. Intake is flexible and can occur with or without food.

The duration of treatment is guided by the clinical context. For the adjuvant setting, the duration is typically five years of continuous therapy. For advanced or metastatic disease, treatment generally continues until tumor progression.

Key Administration Rules

Context	Standard Instruction
Dose	1 mg tablet
Frequency	Once daily (qDay)
Missed Dose	Skip missed dose; take next dose at usual time.
Elderly Dosing	No dosage adjustment needed.

The 1 mg dose remains uniform for most patients. No dosage adjustment is necessary for older adults, nor is one recommended for patients with mild or moderate renal or hepatic impairment. If a daily dose is missed, standard procedure is to skip the missed tablet and take the next dose at its regular schedule; two doses must not be taken together.

Research Evidence / Overview of Studies

Early Research and Preliminary Studies

Research has explored whether anastrozole is associated with changes in breast cancer progression in postmenopausal women with hormone receptor-positive tumors. Studies investigated the hypothesis that the selective inhibition of the aromatase enzyme may be related to outcomes by reducing circulating estrogen levels, which is the mechanism of action.

Clinical Trial Findings

Primary Efficacy Studies

Clinical trials evaluated whether the drug showed changes in disease-free survival in the adjuvant setting. For advanced disease, studies assessed objective response rates. For instance, in one major trial, 85% of participants met the defined endpoint criteria (e.g., complete response, partial response, or stable disease for a specified period). Studies examined the duration of benefits and found that they may persist following the cessation of treatment.

Comparison Studies

Comparative research compared outcomes associated with anastrozole versus tamoxifen. Large-scale trials found that anastrozole satisfied pre-defined criteria for equivalence to tamoxifen in key efficacy measures, and some data indicated a reduction in the incidence of thromboembolic events and vaginal bleeding when compared to tamoxifen. The analysis showed varying data when evaluating the long-term overall survival outcomes across different studies.

Studies on Combination Use

Studies evaluated whether the combination is associated with changes in patient outcomes when the drug was administered alongside other endocrine therapies, such as fulvestrant. Research suggests that combining anastrozole with fulvestrant may be associated with longer progression-free and overall survival compared to anastrozole alone, although one meta-analysis did not find solid evidence supporting this combined approach at lower fulvestrant doses. The evidence remains limited regarding the use of anastrozole in combination with other pharmacological agents for all potential indications.

Key Studies & References

1. NICE Guideline NG101: Early and locally advanced breast cancer: diagnosis and management
2. FALCON: Anastrozole vs Fulvestrant for Advanced Breast Cancer. Efficacy and Safety Study

Common questions about Anastrol (FAQ)

Q: Why is Anastrol prescribed to some women?

Official documents indicate that the medicine is used in the management of hormone receptor-positive breast cancer. Its use is specifically designated for postmenopausal women in various treatment settings, including the early, advanced, or metastatic stages of the disease.

Q: Will Anastrol cause changes to my weight?

Official information derived from clinical trials indicates that weight changes can occur. Weight gain was reported as an adverse reaction in some studies, with an incidence of approximately 9% of patients in one major trial.

Q: Can Anastrol be taken with common pain relievers?

The medicine is generally considered unlikely to cause clinically significant drug interactions through the major Cytochrome P450 enzyme pathways, which are responsible for breaking down many other medicines. However, official labeling notes a potential minor interaction with aspirin that could affect metabolism. Official patient information suggests consulting a healthcare provider regarding all current medications and supplements.

Q: Does Anastrol affect bone density?

Regulatory documents state that use of this medicine is associated with a decrease in bone mineral density (BMD) over time. This effect may lead to an increased risk of fracture. Due to this association, official guidance emphasizes the importance of monitoring bone health.

Q: What is the difference between Anastrol and similar medicines?

Anastrol is classified as a non-steroidal Aromatase Inhibitor (AI). Its mechanism of action—inhibiting the enzyme that produces estrogen—differs from other agents like Tamoxifen, which work by blocking estrogen effects at the receptor level. Comparative studies have also shown differences in the safety profiles between the drug and Tamoxifen.

Q: How quickly does Anastrol leave the system if I stop taking it?

Official pharmacokinetic data indicates that the medicine has a mean terminal elimination half-life of approximately 50 hours in postmenopausal women. The half-life refers to the time it takes for the concentration of the drug in the bloodstream to decrease by half after the final dose.

Q: Does Anastrol affect fertility?

The medicine is officially contraindicated for use in women of premenopausal endocrine status, including those who are pregnant or breastfeeding. Nonclinical studies have examined the potential for impairment of fertility. Refer to the official eligibility criteria for specific population restrictions, as established in regulatory documents.

Q: What is the success rate described in clinical trials for Anastrol?

Efficacy in clinical trials is generally measured by clinical endpoints such as Disease-Free Survival (DFS). In major comparative studies, the drug demonstrated superior DFS compared to Tamoxifen, leading to a 17% relative risk reduction in the primary analysis. Clinical studies do not typically provide a single 'success rate' number.

Q: Does taking Anastrol affect energy levels?

Official information reports that effects on energy levels can occur. Asthenia, which is a general term for weakness or lack of energy, is listed as one of the most common side effects reported in clinical trials, with an incidence of 10% or more in one major study.

Q: Are there any foods or supplements that interact with Anastrol?

The medicine is administered with or without food. Official patient information notes that estrogen-containing herbal products or supplements should be avoided, as these may diminish the intended pharmacological effect of the medicine.

Q: Can men take Anastrol for any approved conditions?

The official indications listed by regulatory bodies specify the use of the medicine for the treatment of breast cancer in postmenopausal women. The product information does not list any currently approved uses for men.

Q: What if I experience side effects that are not listed in the patient leaflet?

Official patient counseling information emphasizes the importance of promptly reporting all unusual or severe symptoms to a healthcare professional. This guidance applies even if the symptoms are not listed among the commonly known side effects.

Q: Is Anastrol safe to take if I have liver problems?

According to official product information, no dosage adjustment is typically needed for patients with mild-to-moderate hepatic impairment or stable hepatic cirrhosis. However, the drug has not been formally studied in patients with severe hepatic impairment.

Q: Can Anastrol affect my sleep?

Official regulatory documents list effects on sleep as a potential side effect. Insomnia, which is difficulty falling or staying asleep, is reported as one of the most common side effects in clinical trials, with an incidence of 10% or more in one major study.

Q: Is Anastrol used to treat conditions other than what it's mainly approved for?

The approved uses for the drug are restricted to the treatment of hormone receptor-positive breast cancer in postmenopausal women in specific settings, as designated in official labeling.

Q: Does Anastrol cause hair thinning?

Official product information reports that hair thinning, also medically known as alopecia, has been observed and reported as an adverse reaction during the use of this medicine.

Q: Can Anastrol cause mood swings?

Official regulatory data lists depression as one of the most common side effects reported in clinical trials, with an incidence of 10% or more in one major study. Depression is a type of mood disturbance.

Storage Requirements

Anastrozole must be stored at Controlled Room Temperature, which is typically defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original container and the container must remain tightly closed to protect the film-coated tablets from excess heat and moisture. Storage above 30 C is generally prohibited, and the medicine must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired anastrozole should not be disposed of in the household trash or by flushing down a drain, which protects against environmental exposure. The officially documented method for disposal is the use of a drug take-back program or mail-back option, if available. If no official program is accessible, the medicine should be mixed with an undesirable substance and placed in a sealed bag before being discarded in the household trash.